|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
ATE207080T1
(de)
|
1991-11-25 |
2001-11-15 |
Enzon Inc |
Multivalente antigen-bindende proteine
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
WO2000067796A1
(en)
|
1999-05-07 |
2000-11-16 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
|
AU2001259142C1
(en)
|
2000-04-25 |
2006-11-23 |
Biogen Idec Inc. |
Intrathecal administration of rituximab for treatment of central nervous system lymphomas
|
|
JP4384852B2
(ja)
|
2001-01-17 |
2009-12-16 |
イントリート ピーティーワイ リミテッド |
非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
|
|
WO2004079013A1
(en)
|
2003-03-03 |
2004-09-16 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
|
|
EP1613350B1
(en)
|
2003-04-09 |
2009-03-18 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
|
EP1639014B1
(en)
|
2003-06-13 |
2010-09-22 |
Biogen Idec MA Inc. |
Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
|
|
AU2004266159A1
(en)
|
2003-08-22 |
2005-03-03 |
Biogen Idec Ma Inc. |
Improved antibodies having altered effector function and methods for making the same
|
|
WO2006125140A2
(en)
|
2005-05-18 |
2006-11-23 |
Biogen Idec Inc. |
Methods for treating fibrotic conditions
|
|
JP5382692B2
(ja)
|
2006-07-10 |
2014-01-08 |
学校法人藤田学園 |
抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
|
|
EP2347769A1
(en)
|
2010-01-20 |
2011-07-27 |
Glycotope GmbH |
Cancer stem cell markers and uses thereof
|
|
CA2848985A1
(en)
*
|
2012-02-01 |
2013-08-08 |
Compugen Ltd. |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
US9090697B2
(en)
|
2013-03-15 |
2015-07-28 |
Bayer Healthcare Llc |
Methods for treating bleeding disorders
|
|
WO2014153424A1
(en)
|
2013-03-19 |
2014-09-25 |
La Jolla Institute For Allergy And Immunology |
Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
|
|
US20180030144A1
(en)
|
2014-10-10 |
2018-02-01 |
Innate Pharma |
Cd73 blockade
|
|
EP3204417B1
(en)
|
2014-10-10 |
2020-07-22 |
Innate Pharma |
Cd73 blockade
|
|
WO2016131950A1
(en)
|
2015-02-20 |
2016-08-25 |
Innate Pharma |
Cd73 blockade
|
|
GB2537445A
(en)
|
2014-11-10 |
2016-10-19 |
Medimmune Ltd |
Binding molecules specific for CD73 and uses thereof
|
|
GB2538120A
(en)
|
2014-11-11 |
2016-11-09 |
Medimmune Ltd |
Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
|
|
AU2015349878A1
(en)
|
2014-11-21 |
2017-05-25 |
Bristol-Myers Squibb Company |
Antibodies against CD73 and uses thereof
|
|
US11130817B2
(en)
|
2015-10-12 |
2021-09-28 |
Innate Pharma |
CD73 blocking agents
|
|
CN114805575B
(zh)
|
2015-12-09 |
2024-07-23 |
科尔沃斯制药股份有限公司 |
人源化抗cd73抗体
|
|
EP3423494A1
(en)
*
|
2016-03-04 |
2019-01-09 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
|
WO2018013611A1
(en)
|
2016-07-11 |
2018-01-18 |
Corvus Pharmaceuticals, Inc. |
Anti-cd73 antibodies
|
|
RU2754058C2
(ru)
|
2016-12-13 |
2021-08-26 |
Астеллас Фарма Инк. |
Антитело к cd73 человека
|
|
CA3045376C
(en)
|
2017-01-24 |
2022-08-30 |
I-Mab |
Anti-cd73 antibodies and uses thereof
|
|
US20210107989A1
(en)
|
2017-04-04 |
2021-04-15 |
Corvus Pharmaceuticals, Inc. |
Methods for treating cd73hi tumors
|
|
US11530273B2
(en)
|
2017-05-23 |
2022-12-20 |
Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
|
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TWI877770B
(zh)
|
2018-02-27 |
2025-03-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
|
|
WO2019170131A1
(zh)
|
2018-03-07 |
2019-09-12 |
复旦大学 |
靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
|
|
EP3762030A4
(en)
*
|
2018-03-09 |
2022-01-05 |
Phanes Therapeutics, Inc. |
ANTI-CD73 ANTIBODIES AND USES THEREOF
|
|
WO2019173692A2
(en)
*
|
2018-03-09 |
2019-09-12 |
Agenus Inc. |
Anti-cd73 antibodies and methods of use thereof
|
|
US11220510B2
(en)
|
2018-04-09 |
2022-01-11 |
Incyte Corporation |
Pyrrole tricyclic compounds as A2A / A2B inhibitors
|
|
BR112020020826A2
(pt)
|
2018-04-12 |
2021-01-19 |
Bristol-Myers Squibb Company |
Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
|
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
WO2019232244A2
(en)
*
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
WO2020010197A1
(en)
|
2018-07-05 |
2020-01-09 |
Incyte Corporation |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
|
MX2021005248A
(es)
|
2018-11-05 |
2021-08-11 |
Corvus Pharmaceuticals Inc |
Anticuerpos contra cd73 activadores de células b.
|
|
US20220220218A1
(en)
|
2018-11-12 |
2022-07-14 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
|
|
CN111499747B
(zh)
|
2019-01-11 |
2022-03-18 |
康诺亚生物医药科技（成都）有限公司 |
一种抗cd73单克隆抗体及其应用
|
|
CN111434688A
(zh)
|
2019-01-11 |
2020-07-21 |
上海开拓者生物医药有限公司 |
Cd73抗体及其制备方法和应用
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
MX2021012769A
(es)
|
2019-04-23 |
2021-11-18 |
Innate Pharma |
Anticuerpos bloqueadores cd73.
|
|
JP7623706B2
(ja)
|
2019-06-06 |
2025-01-29 |
ジャコバイオ ファーマスーティカルズ カンパニー リミテッド |
Ｃｄ７３に特異的な結合分子と結合分子の使用
|
|
CN117946274B
(zh)
|
2019-06-19 |
2026-02-17 |
杭州博之锐生物制药有限公司 |
抗cd73抗体及其应用
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
JP7471016B2
(ja)
|
2019-08-21 |
2024-04-19 |
ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド |
抗ｃｄ７３抗体およびその適用
|
|
PE20230372A1
(es)
|
2019-08-26 |
2023-03-06 |
Incyte Corp |
Triazolopirimidinas como inhibidores de a2a/a2b
|
|
UA130408C2
(uk)
|
2019-09-06 |
2026-02-11 |
Ле Лаборатуар Сервьє |
Антитіла до cd73
|
|
US20240218073A1
(en)
|
2019-11-01 |
2024-07-04 |
Corvus Pharmaceuticals, Inc. |
Immunomodulatory anti-cd73 antibodies and uses thereof
|
|
CA3161717A1
(en)
|
2019-11-15 |
2021-05-20 |
Dana LORD |
Biparatopic cd73 antibodies
|
|
CA3165384A1
(en)
|
2019-12-19 |
2021-06-24 |
Board Of Regents, The University Of Texas System |
Methods for treating glioblastoma
|
|
TW202135823A
(zh)
|
2020-01-03 |
2021-10-01 |
美商英塞特公司 |
Ｃｄ７３抑制劑及ａ２ａ／ａ２ｂ腺苷受體抑制劑組合療法
|
|
PE20221409A1
(es)
|
2020-01-03 |
2022-09-20 |
Incyte Corp |
Anticuerpos anti-cd73 y usos de estos
|
|
CA3174033A1
(en)
|
2020-04-09 |
2021-10-14 |
Sang Hoon Cha |
Monoclonal antibodies and antigen binding fragments thereof for suppressing cd73 immune checkpoint and uses thereof
|
|
US20230159655A1
(en)
|
2020-04-22 |
2023-05-25 |
Akeso Biopharma, Inc |
Anti-cd73 antibody and use thereof
|
|
CN115551888B
(zh)
|
2020-05-12 |
2026-04-28 |
百欧恩泰(珠海)医药研发有限公司 |
抗cd73抗体及其用途
|
|
EP4159763A4
(en)
|
2020-05-29 |
2024-06-12 |
BrightPath Biotherapeutics Co., Ltd. |
ANTI-CD73 ANTIBODIES AND USE THEREOF
|
|
JP2023532234A
(ja)
|
2020-06-22 |
2023-07-27 |
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド |
抗ｃｄ７３抗体とその用途
|
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
|